Mammoth Biosciences

Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics

Gene editing

Home » Emerging technologies » Gene editing » Page 2

mushroom

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement

mushroom

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease

Could Crispr Eradicate Acne?

mushroom

Editas Medicine Announces The FDA Has Cleared Initiation Of The EDIT-301 Clinical Trial

mushroom

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

mushroom

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

mushroom

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Intellia Therapeutics

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

These CRISPR Edited Seeds Are Planting A Sustainable Future For The Agricultural Industry

Recombia Biosciences

Lesaffre and Recombia Biosciences to advance innovative gene editing technology through a strategic partnership